Abstract
Insufficient efficacy of current single drug therapy of cancers have led to the advancement of combination drug-loaded formulations. Specifically, polymeric micelles have been focused on as efficient injectable vehicles for the delivery of several anticancer drugs simultaneously to cancer cells. These nano delivery systems have evolved with advancements in the area of nanotechnology. The current review presents a summary of the past events that have led to the procession of nanomicelles and novel nanotechnologies for combinatorial drug delivery. It also focuses on the advantages, disadvantages, and considerations for the design of nanotechnologies for combinatorial drug delivery systems. The opportunities and challenges of nanotechnologies in drug delivery to overcome current disadvantages are also discussed. Furthermore, we have added findings regarding the trends and perspectives regarding nanotechnologies for combinatorial anticancer drug delivery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abu Lila AS, Kiwada H, Ishida T (2013) The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 172:38–47. https://doi.org/10.1016/j.jconrel.2013.07.026
Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60:5761–5766.
Andreuccetti M, Allegrini G, Antonuzzo A, Malvaldi G, Conte PF, Danesi R, Del Tacca M, Falcone A (1996) Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and dna-induced strand-breaks. Eur J Cancer 32:1219–1226. https://doi.org/10.1016/0959-8049(96)00018-4
Arpagaus C (2019) PLA/PLGA nanoparticles prepared by nano spray drying. J Pharm Investig 49:405–426. https://doi.org/10.1007/s40005-019-00441-3
Aw MS, Kurian M, Losic D (2013) Polymeric micelles for multidrug delivery and combination therapy. Chemistry 19:12586–12601. https://doi.org/10.1002/chem.201302097
Bavli Y, Winkler I, Chen BM, Roffler S, Cohen R, Szebeni J, Barenholz Y (2019) Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. J Control Release 306:138–148. https://doi.org/10.1016/j.jconrel.2019.06.007
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410. https://doi.org/10.1056/nejm197602192940801
Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011–1016. https://doi.org/10.1097/00001813-200211000-00005
Chabner BA, Roberts TG Jr (2005) Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72. https://doi.org/10.1038/nrc1529
Chen H, Kim S, He W, Wang H, Low PS, Park K, Cheng J-X (2008) Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Förster resonance energy transfer imaging. Langmuir 24:5213–5217. https://doi.org/10.1021/la703570m
Chen C, Tao R, Ding D, Kong D, Fan A, Wang Z, Zhao Y (2017) Ratiometric co-delivery of multiple chemodrugs in a single nanocarrier. Eur J Pharm Sci 107:16–23. https://doi.org/10.1016/j.ejps.2017.06.030
Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440. https://doi.org/10.1158/0008-5472.CAN-09-1947
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4
Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP (2003) Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 4:760–768. https://doi.org/10.1016/S1470-2045(03)01282-8
DeVita VT Jr, Young RC, Canellos GP (1975) Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98–110. https://doi.org/10.1002/1097-0142(197501)35:1%3c98:aid-cncr2820350115%3e3.0.co;2-b
Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 113:772–778. https://doi.org/10.1046/j.1365-2141.2001.02795.x
Elmowafy EM, Tiboni M, Soliman ME (2019) Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J Pharm Investig 49:347–380. https://doi.org/10.1007/s40005-019-00439-x
Emami F, Mostafavi Yazdi SJ, Na DH (2019) Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery. J Pharm Investig 49:427–442. https://doi.org/10.1007/s40005-019-00443-1
Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G (1985) Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3:65–71. https://doi.org/10.1200/jco.1985.3.1.65
Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598. https://doi.org/10.1016/S0959-8049(01)00171-X
Gerweck LE (1998) Tumor pH: Implications for treatment and novel drug design. Semin Radiat Oncol 8:176–182. https://doi.org/10.1016/S1053-4296(98)80043-X
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627. https://doi.org/10.1146/annurev.med.53.082901.103929
Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 105:11613–11618. https://doi.org/10.1073/pnas.0801763105
Greish K (2010) Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 624:25–37. https://doi.org/10.1007/978-1-60761-609-2_3
Harper PG, Dally MB, Geddes DM, Spiro SG, Smyth JF, Souhami RL (1982) Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy. Cancer Chemother Pharmacol 7:179–180. https://doi.org/10.1007/bf00254544
Hasenstein JR, Shin HC, Kasmerchak K, Buehler D, Kwon GS, Kozak KR (2012) Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther 11:2233–2242. https://doi.org/10.1158/1535-7163.mct-11-0987
Henriksson R, Grankvist K (1989) Interactions between anticancer drugs and other clinically used pharmaceuticals. A review. Acta Oncol 28:451–462. https://doi.org/10.3109/02841868909092250
Herman EH, Witial DT, Hellmann K, Waravdekar VS (1982) Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. In: Garattini S, Goldin A, Hawking F, Kopin IJ, Schnitzer RJ (eds) Advances in pharmacology. Academic Press, Cambridge, vol 19, pp 249–290. https://doi.org/10.1016/S1054-3589(08)60025-3.
Higby DJ, Wallace HJ Jr, Holland JF (1973) Cis-diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 57:459–463
Hu Q, Sun W, Wang C, Gu Z (2016) Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 98:19–34. https://doi.org/10.1016/j.addr.2015.10.022
Huang Y, Johnson KR, Norris JS, Fan W (2000) Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60:4426.
Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A (2018) Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 68:31–54. https://doi.org/10.3322/caac.21440
Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T, Tomita M, Kawaguchi M, Kobashi H, Sakaguchi K, Shiratori Y (2006) Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:54–63. https://doi.org/10.1002/hep.20984
Jaeryun L, Deokbae P, Youngki L (2017) Metformin synergistically potentiates the antitumor effects of imatinib in colorectal cancer cells. Dev Rerprod 21:139–150. https://doi.org/10.12717/DR.2017.21.2.139
Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. MOL CELL BIOCHEM 234:119–124. https://doi.org/10.1023/A:1015976430790
Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72:191–202. https://doi.org/10.1016/s0168-3659(01)00275-9
Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716. https://doi.org/10.1158/1078-0432.ccr-03-0655
Kostková H, Etrych T, Říhová B, Kostka L, Starovoytová L, Kovář M, Ulbrich K (2013) HPMA copolymer conjugates of DOX and Mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy. Macromol Biosci 13:1648–1660. https://doi.org/10.1002/mabi.201300288
Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, Sonoo H (2006) Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58:460–470. https://doi.org/10.1007/s00280-006-0185-x
Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J (2008) Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241–250. https://doi.org/10.1007/s10549-007-9591-y
Logue JS, Morrison DK (2012) Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 26:641–650. https://doi.org/10.1101/gad.186965.112
Ma J, Kang K, Yi Q, Zhang Z, Gu Z (2016) Multiple pH responsive zwitterionic micelles for stealth delivery of anticancer drugs. RSC Advances 6:64778–64790. https://doi.org/10.1039/C6RA11645K
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284. https://doi.org/10.1016/s0168-3659(99)00248-5
Markovsky E, Baabur-Cohen H, Satchi-Fainaro R (2014) Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. J Control Release 187:145–157. https://doi.org/10.1016/j.jconrel.2014.05.025
Mayer LD, Janoff AS (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7:216–223. https://doi.org/10.1124/mi.7.4.8
Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D'Incalci M, Riccardi R (2003) Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 52:131–138. https://doi.org/10.1007/s00280-003-0636-6
Merlin J-L, Barberi-Heyob M, Bachmann N (2002) In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Ann Oncol 13:1743–1748. https://doi.org/10.1093/annonc/mdf263
Mirhadi E, Nassirli H, Malaekeh-Nikouei B (2020) An updated review on therapeutic effects of nanoparticle-based formulations of saffron components (safranal, crocin, and crocetin). J Pharm Investig 50:47–58. https://doi.org/10.1007/s40005-019-00435-1
Nandhakumar S, Dhanaraju MD, Sundar VD, Heera B (2017) Influence of surface charge on the in vitro protein adsorption and cell cytotoxicity of paclitaxel loaded poly(ε-caprolactone) nanoparticles. Bull Fac Pharm Cairo Univ 55:249–258. https://doi.org/10.1016/j.bfopcu.2017.06.003
Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599–606.
O'Reilly RK, Hawker CJ, Wooley KL (2006) Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility. Chem Soc Rev 35:1068–1083. https://doi.org/10.1039/B514858H
Ouahab A, Shao C, Shen Y, Tu J (2014) Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel. Drug Dev Ind Pharm 40:860–868. https://doi.org/10.3109/03639045.2013.788017
Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW (2002) Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther 5:463–472. https://doi.org/10.1006/mthe.2002.0568
Perinelli DR, Cespi M, Bonacucina G, Palmieri GF (2019) PEGylated polylactide (PLA) and poly (lactic-co-glycolic acid) (PLGA) copolymers for the design of drug delivery systems. J Pharm Investig 49:443–458. https://doi.org/10.1007/s40005-019-00442-2
Pienta KJ (2001) Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28:3–7. https://doi.org/10.1016/s0093-7754(01)90148-4
Roell KR, Reif DM, Motsinger-Reif AA (2017) An Introduction to terminology and methodology of chemical synergy—perspectives from across disciplines. Front Pharmacol 8:1–11. https://doi.org/10.3389/fphar.2017.00158
Savage DG, Rule SAI, Tighe M, Garrett TJ, Oster WM, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, Johnson SA (2000) Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 11:595–597. https://doi.org/10.1023/A:1008307528519
Shaw G, Prowse DM (2008) Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int 8:3. https://doi.org/10.1186/1475-2867-8-3
Shin HC, Alani AW, Cho H, Bae Y, Kolesar JM, Kwon GS (2011) A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm 8:1257–1265. https://doi.org/10.1021/mp2000549
Shin DH, Tam YT, Kwon GS (2016) Polymeric micelle nanocarriers in cancer research. Front Chem Sci Eng 10:348–359. https://doi.org/10.1007/s11705-016-1582-2
Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M (1993) Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167–172. https://doi.org/10.1007/bf00685830
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA-CANCER J CLIN 67:7–30. https://doi.org/10.3322/caac.21387
Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou T-C, Scotto KW, Bertino JR (2002) Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines. Cancer Res 62:6909–6915.
Tallarida RJ, Raffa RB (2010) The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther 127:165–174. https://doi.org/10.1016/j.pharmthera.2010.04.011
Tam YT, Repp L, Ma ZX, Feltenberger JB, Kwon GS (2019) Oligo(lactic acid)8-rapamycin prodrug-loaded poly(ethylene glycol)-block-poly(lactic acid) micelles for injection. Pharm Res 36:70. https://doi.org/10.1007/s11095-019-2600-0
Tempero M, Kessinger A, Lemon HM (1981) VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. Cancer Clin Trials 4:155–157. https://doi.org/10.1200/JCO.1984.2.12.1343
Tomoda K, Tam YT, Cho H, Buehler D, Kozak KR, Kwon GS (2017) Triolimus: a multi-drug loaded polymeric micelle containing paclitaxel, 17-AAG, and rapamycin as a novel radiosensitizer. Macromol Biosci. https://doi.org/10.1002/mabi.201600194
Tran BN, Nguyen HT, Kim JO, Yong CS, Nguyen CN (2017) Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment. Arch Pharm Res 40:1420–1432. https://doi.org/10.1007/s12272-017-0968-0
Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D (1998) Antifungal drug resistance in pathogenic fungi. Med Mycol 36(Suppl 1):119–128. https://doi.org/10.1086/344058
Yabroff KR, Lund J, Kepka D, Mariotto A (2011) Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20:2006–2014. https://doi.org/10.1158/1055-9965.epi-11-0650
Zamble DB, Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20:435–439. https://doi.org/10.1016/s0968-0004(00)89095-7
Zhang H, Wang G, Yang H (2011) Drug delivery systems for differential release in combination therapy. Expert Opin Drug Deliv 8:171–190. https://doi.org/10.1517/17425247.2011.547470
Acknowledgements
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R1C1C1009996).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jo, M.J., Jin, I.S., Park, CW. et al. Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery. Arch. Pharm. Res. 43, 100–109 (2020). https://doi.org/10.1007/s12272-020-01215-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01215-4